Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer
- 30 August 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (17), 5838-5849
- https://doi.org/10.1158/0008-5472.can-11-0994
Abstract
Small-molecule inhibitors of Hsp90 show promise in the treatment of castrate-resistant prostate cancer (CRPC); however, these inhibitors trigger a heat shock response that attenuates drug effectiveness. Attenuation is associated with increased expression of Hsp90, Hsp70, Hsp27, and clusterin (CLU) that mediate tumor cell survival and treatment resistance. We hypothesized that preventing CLU induction in this response would enhance Hsp90 inhibitor–induced CRPC cell death in vitro and in vivo. To test this hypothesis, we treated CRPC with the Hsp90 inhibitor PF-04929113 or 17-AAG in the absence or presence of OGX-011, an antisense drug that targets CLU. Treatment with either Hsp90 inhibitor alone increased nuclear translocation and transcriptional activity of the heat shock factor HSF-1, which stimulated dose- and time-dependent increases in HSP expression, especially CLU expression. Treatment-induced increases in CLU were blocked by OGX-011, which synergistically enhanced the activity of Hsp90 inhibition on CRPC cell growth and apoptosis. Accompanying these effects was a decrease in HSF-1 transcriptional activity as well as expression of HSPs, Akt, prostate-specific antigen, and androgen receptor. In vivo evaluation of the Hsp90 inhibitors with OGX-011 in xenograft models of human CRPC showed that OGX-011 markedly potentiated antitumor efficacy, leading to an 80% inhibition of tumor growth with prolonged survival compared with Hsp90 inhibitor monotherapy. Together, our findings indicate that Hsp90 inhibitor–induced activation of the heat shock response and CLU is attenuated by OGX-011, with synergistic effects on delaying CRPC progression. Cancer Res; 71(17); 5838–49. ©2011 AACR.Keywords
Other Versions
This publication has 39 references indexed in Scilit:
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerClinical Cancer Research, 2010
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerClinical Cancer Research, 2009
- Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesisOncogene, 2009
- Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin DCancer Research, 2009
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKBlood, 2009
- SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent CancersClinical Cancer Research, 2008
- Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of CarcinogenesisCell, 2007
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Proceedings of the National Academy of Sciences of the United States of America, 2006
- Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy GeldanamycinCancer Research, 2005
- Prostate specific antigen gene regulation by androgen receptorJournal of Cellular Biochemistry, 2004